NuProbe Announces $11 Million Series A Funding Round
Molecular diagnostics startup to expand reach of precision medicine
CAMBRIDGE, Mass.–(BUSINESS WIRE)–NuProbe, an early stage molecular diagnostics company, raised $11 million to continue development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases. The Series A funding was co-led by Sequoia China and Serica Partners. Additional investors include WuXi AppTec Corporate Ventures. The funds will be used to grow staff in its Cambridge, Mass. and China offices, and to continue technology development, clinical trials and commercialization.
Developed at and licensed from Harvard University’s Wyss Institute for Biologically Inspired Engineering and Rice University, NuProbe’s toehold probe-based technology is a breakthrough molecular strategy to test for diverse disease signatures, including cancer. NuProbe’s technology is highly sensitive at identifying many variants in the early stages, which can improve detection and help guide treatment decisions that may increase survival for patients.
“NuProbe’s vision is to pioneer technology innovation to advance human health. Its core technology enables effective probing of subtle disease signatures, such as rare mutations in cancer,” said Peng Yin, Ph.D., NuProbe co-founder and Professor of Systems Biology at Wyss Institute and Harvard Medical School. “We aspire to expand the reach of precision medicine with transformative innovations.”
In pre-clinical trials, NuProbe’s technology improved qPCR and NGS mutation detection sensitivity by 10-100 fold with limit of detection down to 0.01 percent, and showed a multiplexing capability of 10-100 reactions for detecting hundreds of mutations in the same test tube.
“Our technology provides uniquely high sensitivity and multiplexing capability for non-invasive cell-free DNA detection in blood,” said David Yu Zhang, Ph.D., NuProbe co-founder and the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. “We are optimistic about the value of our technology in optimizing treatment, monitoring disease, screening for early stages of disease and other applications of genomics as applied to human health.”
“NuProbe’s technology has been validated for highly sensitive and comprehensive capturing of disease signatures with simple and clinically compatible workflow,” said Victor Shi, Ph.D., NuProbe co-founder and CEO, and Managing Partner of Serica Partners. “With the endorsement and strong support from investors, we are on track to commercialize the technology, allowing more patient access to these powerful tests.”
“The sensitivity and broad applicability of NuProbe’s technology holds unique potential in molecular diagnostics,” said Founding and Managing Partner of Sequoia Capital China, Neil Shen. “We are delighted to support NuProbe team’s ground breaking work to realize the promise of precision medicine.”
NuProbe’s vision is to pioneer technology innovation to advance human health. Its technology enables precise and comprehensive capturing of disease signatures with uniquely high sensitivity and multiplexing capability. The proprietary and patented technology is compatible with common PCR and sequencing platforms, and clinical workflow. NuProbe develops multiple platforms for diverse molecular diagnostics applications, including cancer, NIPT, and infectious disease. To learn more, visit www.nuprobe.com.
About Sequoia China
The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 13 years we’ve had the privilege of working with more than 500 companies in China. For more information, visit www.sequoiacap.com/china/en.
About Serica Partners
Serica Partners is a China-based venture fund focusing on investing in innovative companies in medical devices and in vitro diagnostics. The Serica team has more than 20 years expertise in both China and the United States healthcare industry, and has participated in many successful venture creations and investments. With deep professional knowledge, extensive network, and prestigious reputation in the medical technology industry, we build industry ecosystems and project source networks. The Serica team is keen to identify the most valuable product/startup team and is committed to making distinctive cross-border cooperative investment.
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling over 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”